Oral insulin: The rationale for this approach and current developments

Journal of Diabetes Science and Technology

Volumn 3, Issue 3, 2009, Pages 562-567

  Arbit, Ehud ^a   Kidron, Miriam ^a,b  

^a Oramed Pharmaceuticals   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Diabetes; Glucose metabolism; Insulin; Liver; Oral antidiabetic medication; Portal vein

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

BLOOD; DIABETES MELLITUS; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BIOLOGICAL TRANSPORT; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 72749107757     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300322     Document Type: Review

References (36)

1. Meier JJ, Holst JJ, Schmidt WE, Nauck MA. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am J Physiol Endocrinol Metab. 2007;293(3):E849-56.
2. Eaton RP, Allen RC, Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab 1983;56(6):1294-300.
3. Meistas MT, Rendell M, Margolis S, Kowarski AA. Estimation of the secretion rate of insulin from the urinary excretion rate of C-peptide. Study in obese and diabetic subjects. Diabetes. 1982;31(5 Pt 1):449-453.
4. Satake S, Moore MC, Igawa K, Converse M, Farmer B, Neal DW, Cherrington AD. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes. 2002;51(6):1663-71.
5. Camacho RC, Pencek RR, Lacy DB, James FD, Wasserman DH. Suppression of endogenous glucose production by mild hyperinsulinemia during exercise is determined predominantly by portal venous insulin. Diabetes. 2004;53(2):285-93.
6. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326(1):22-9.
7. Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2004;287(6):E1049-56.
8. Firth RG, Bell PM, Rizza RA. Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1986;314(20):1280-6.
9. Cherrington AD, Sindelar D, Edgerton D, Steiner K, McGuinness OP. Physiological consequences of phasic insulin release in the normal animal. Diabetes. 2002;51 Suppl 1:S103-8.
10. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes. 1998;47(4):523-9.
11. Basu R, Basu A, Johnson CM, Schwenk WF, Rizza RA. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes. 2004;53(8):2042-50.
12. Staehr P, Hother-Nielsen O, Levin K, Holst JJ, Beck-Nielsen H. Assessment of hepatic insulin action in obese type 2 diabetic patients. Diabetes. 2001;50(6):1363-70.
13. Kim SH, Reaven GM. Insulin resistance and hyperinsulinemia: you can't have one without the other. Diabetes Care. 2008;31(7):1433-8.
14. Bonora E, Capaldo B, Perin PC, Del Prato S, De Mattia G, Frittitta L, Frontoni S, Leonetti F, Luzi L, Marchesini G, Marini MA, Natali A, Paolisso G, Piatti PM, Pujia A, Solini A, Vettor R, Bonadonna RC; Group of Italian Scientists of Insulin Resistance (GISIR). Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr Metab Cardiovasc Dis. 2008;18(9):624-31.
15. Shishko PI, Kovalev PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes. 1992;41(9):1042-9.
16. Shuster LT, Go VL, Rizza RA, O'Brien PC, Service FJ. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes. 1988;37(2):200-3.
17. De Vos P, De Haan BJ, Vegter D, Hillebrands JL, Strubbe JH, Bruggink JE, Van Schilfgaarde R. Insulin levels after portal and systemic insulin infusion differ in a dose-dependent fashion. Horm Metab Res. 1998;30(12):721-5.
18. Jeandidier N, Selam JL, Renard E, Guerci B, Lassman-Vague V, Rocher L, Hanaire-Broutin H. Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Evadiac Study Group. Diabetes Care. 1996;19(7):780.
19. Schade DS, Eaton RP, Friedman NM, Spencer WJ. Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia. 1980;19(1):35-39.
20. Selgas R, Diez JJ, Munoz J, Miranda B, de Alvaro F, Rodriguez JC. Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study. Adv Perit Dial. 1989;5:181-4.
21. Scarpioni L, Ballocchi S, Castelli A, Scarpioni R. Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration. Perit Dial Int. 1994;14(2):127-31.
22. Lahtela JT, Mustonen J, Pasternack A. Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type I diabetic patients on continuous ambulatory peritoneal dialysis treatment. Clin Sci (Lond). 1995;88(4):427-32.
23. Hanaire-Broutin H, Broussolle C, Jeandidier N, Renard E, Guerci B, Haardt MJ, Lassmann-Vague V. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabete du Traitement par Implants Actifs. Diabetes Care. 1995;18(3):388-92.
24. Luzi L, Hering BJ, Socci C, Raptis G, Battezzati A, Terruzzi I, Falqui L, Brandhorst H, Brandhorst D, Regalia E, Brambilla E, Secchi A, Perseghin G, Maffi P, Bianchi E, Mazzaferro V, Gennari L, Di Carlo V, Federlin K, Pozza G, Bretzel RG. Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus. J Clin Invest. 1996;97(11):2611-8.
25. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AM, Vantyghem MC. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955-62.
26. Fiorina P, Shapiro AM, Ricordi C, Secchi A. The clinical impact of islet transplantation. Am J Transplant. 2008;8(10):1990-7.
27. Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. b-Cell function following human islet transplantation for type 1 diabetes. Diabetes. 2005;54(1):100-6.
28. Perriello G, Jorde R, Nurjhan N, Stumvoll M, Dailey G, Jenssen T, Bier DM, Gerich JE. Estimation of glucose-alanine-lactate-glutamine cycles in postabsorptive humans: role of skeletal muscle. Am J Physiol. 1995;269(3 Pt 1):E443-50.
29. Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 1995;6(2):164-79.
30. Argiles JM, Lopez-Soriano FJ. Insulin and cancer (Review). Int J Oncol. 2001;18(4):683-7.
31. Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D, De Meyts P. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia. 1997;40 Suppl 2:S25-31.
32. Dave N, Hazra P, Khedkar A, Manjunath HS, Iyer H, Suryanarayanan S. Process and purification for manufacture of a modified insulin intended for oral delivery. J Chromatogr A. 2008;1177(2):282-6.
33. Iyer H, Khedkar AP, Suryanarayan S, Anand A, Vedala A, Krishnamurthy S, Arvind AS, Eshwaraiah A, Savale S, Prasanna Kumar KM, Arvind SR, Srikanta SS. An open label, two period, placebo controlled, multiple dose study to evaluate the effect of food on pharmacokinetic and pharmacodynamic of IN-105 10 mg in type 2 diabetes mellitus patients. European Association Study of Diabetes Rome, Italy; 2008.
34. Broke-Smith T, Luzio S, Lockett A, New R, Owens D. Repeat-dosing of oral insulin (capsulin) in persons with type 2 diabetes. European Association for the Study of Diabetes 44th Annual Meeting Rome, Italy; 2008.
35. Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, Arbit E, Bar-On H. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med. 2004;21(4):354-7.
36. Kidron M, Raz IM, Wolfensberger M, Schwob H, Schruefer C. Pharmacokinetics (PK) and pharmacodynamics (PD) of oral insulin in healthy subjects. American Diabetes Association, 68th Annual Meeting San Francisco, CA; 2008.